Adverum Biotechnologies, Inc. (ADVM)

Adverum Biotechnologies Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-184.79	-130.93	-122.12	-154.54	-145.54	-117.51
Depreciation & Amortization	2.49	3.65	5.64	6.53	4.65	4.16
Loss (Gain) From Sale of Assets	0.01	0	0.05	0.12	-	-
Asset Writedown & Restructuring Costs	-	-	-	2.12	1.06	-
Loss (Gain) From Sale of Investments	-1.16	-1.91	-1.94	-0.88	2.77	0.52
Stock-Based Compensation	10.83	14.35	17.57	20.08	25.19	20.39
Other Operating Activities	12.79	21.46	18.39	2.62	-0.03	0.42
Change in Accounts Payable	10.39	-0.26	-0.37	0.85	-1.61	1.59
Change in Other Net Operating Assets	11.54	1.17	-8.14	15	5.67	11.14
Operating Cash Flow	-137.9	-92.46	-90.9	-108.09	-107.83	-79.29
Capital Expenditures	-0.54	-0.39	-0.81	-11.82	-15.12	-11.84
Investment in Securities	61.4	-41.5	97.68	153.54	93.83	-268.32
Investing Cash Flow	60.85	-41.89	96.88	141.72	78.71	-280.17
Long-Term Debt Repaid	-	-	-	-	-0.24	-0.06
Net Debt Issued (Repaid)	-	-	-	-	-0.24	-0.06
Issuance of Common Stock	10.26	120	0.49	0.61	2.64	358.09
Repurchase of Common Stock	-	-	-	-	-	-2.04
Other Financing Activities	-	-	-0.42	-	-	-
Financing Cash Flow	10.26	120	0.07	0.61	2.4	355.99
Net Cash Flow	-66.79	-14.35	6.04	34.24	-26.73	-3.47
Free Cash Flow	-138.45	-92.85	-91.71	-119.91	-122.95	-91.14
Free Cash Flow Margin	-	-9285.00%	-2547.50%	-	-1639.39%	-
Free Cash Flow Per Share	-6.41	-4.69	-9.10	-12.08	-12.54	-10.70
Levered Free Cash Flow	-78.24	-66	-63.92	-72.63	-80.16	-54.76
Unlevered Free Cash Flow	-78.24	-66	-63.92	-72.63	-80.16	-54.76
Change in Working Capital	21.93	0.91	-8.51	15.85	4.06	12.73

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q